e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS

Contributed by: GlobeNewswire

Tags

Biotech

More Like This

Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate

Tangram Therapeutics Announces First Participant Dosed in Phase 1/2 RESTORE-MASH Trial of TGM-312, a Novel Investigational RNAi Medicine

Tangram Announces Oral Presentation of TGM-148 Preclinical Data Highlighting Context-Dependent Mechanism of Action at the American Society of Hematology (ASH) 2026 Annual Meeting

Tangram Therapeutics Announces Progression to Patient Cohorts in Phase 1/2 RESTORE-MASH Trial of TGM-312 and Appointment of Dr Sonya Montgomery as Chief Development Officer

Tangram Announces First Participant Dosed in Phase 1 Trial of TGM-148, a Novel Investigational RNAi Medicine for Bleeding Disorders

e-therapeutics Announces Business Updates and Interim Results

e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025

GlobeNewswire associated0

4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy